source
- FDA grants accelerated approval to first plasmid DNA immunotherapy for adult recurrent respiratory papillomatosisThe U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) as a treatment for adults with recurrent respiratory pa…
- Aspen Neuroscience and Bambusa raise $310M combined in IPOsAspen Neuroscience, a biotech focused on cell therapy for Parkinson's disease, announced it will raise about $141 million through its initial public offering scheduled for Friday. Bambusa, a start…